Drugs Information:
Naloxegol
Basic Information
|
|
||
| ID | DDInter1261 | |
| Drug Type | small molecule | |
| Molecular Formula | C34H53NO11 | |
| Molecular Weight | 651.794 | |
| CAS Number | 854601-70-0 | |
| Description | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier. | |
| ATC Classification | A06AH03 | |
| IUPAC Name | (1S,5R,13R,14S,17S)-14-(2,5,8,11,14,17,20-heptaoxadocosan-22-yloxy)-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-triene-10,17-diol | |
| InChI | XNKCCCKFOQNXKV-ZRSCBOBOSA-N | |
| Canonical SMILES | COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5 | |
| Useful Links | DrugBank ChEBI PubChem Substance KEGG Drug ChemSpider Wikipedia ChEMBL ZINC | |
Interactions with
Naloxegol
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|